Overview
BioMed Innovations is at the forefront of developing innovative gene therapy solutions for rare genetic disorders. Our proprietary technology harnesses the power of CRISPR to precisely edit genes, offering hope to patients who currently have limited treatment options. Over the past 18 months, we have successfully developed our lead candidate therapy, which has shown promising results in preclinical studies. Our initial trials indicate significant efficacy in targeting the underlying genetic causes of these disorders, and we have received positive feedback from regulatory agencies regarding our proposed clinical trial design. Currently, we are seeking an investment of $280,000 to help us scale our operations and expedite our clinical trials. The funds will specifically be used to enhance our laboratory capabilities, secure necessary materials for trial preparation, and cover initial costs associated with patient recruitment. We have already established partnerships with leading academic institutions that are eager to collaborate on the upcoming phases of our clinical studies, which we believe will further validate our technology and approach. In addition to our technical milestones,…
Use of funds
The $280,000 will be allocated as follows:
- Laboratory enhancements: $100,000 for upgraded equipment and facilities to support our expanding research activities.
- Clinical trial preparation: $120,000 for materials, trial management, and compliance measures needed for FDA submissions.
- Patient recruitment and outreach: $60,000 directed toward developing targeted recruitment campaigns and engaging with potential trial participants.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.